Identification of Cisplatin-Binding Proteins Using Agarose Conjugates of Platinum Compounds

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Karasawa, Takatoshi ^a   Sibrian Vazquez, Martha ^b   Strongin, Robert M ^b   Steyger, Peter S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE; AMINE; ANAZOLENE SODIUM; CALRETICULIN; CHLORIDE; CISPLATIN; CISPLATIN BINDING PROTEIN; DRUG BINDING PROTEIN; GLUCOSE REGULATED PROTEIN 94; HEAT SHOCK PROTEIN 90; MYOSIN IIA; PLATINUM DERIVATIVE; RIBOSOMAL PROTEIN L5; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; CDC48 PROTEIN; CELL CYCLE PROTEIN; CELL EXTRACT; ENDOPLASMIN; GLYCOCONJUGATE; MEMBRANE PROTEIN; PROTEIN BINDING; SEPHAROSE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; COCHLEA; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG STRUCTURE; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; KIDNEY CELL; MASS SPECTROMETRY; MOUSE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; STAINING; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHEMISTRY; CORTI ORGAN; CYTOLOGY; EPITHELIUM CELL; ISOLATION AND PURIFICATION; KIDNEY PROXIMAL TUBULE; SYNTHESIS;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS; CALRETICULIN; CELL CYCLE PROTEINS; CELL EXTRACTS; CELL LINE; CISPLATIN; EPITHELIAL CELLS; GLYCOCONJUGATES; HSP90 HEAT-SHOCK PROTEINS; KIDNEY TUBULES, PROXIMAL; MEMBRANE GLYCOPROTEINS; MICE; NONMUSCLE MYOSIN TYPE IIA; ORGAN OF CORTI; PROTEIN BINDING; RIBOSOMAL PROTEINS; SEPHAROSE;

EID: 84878656881     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066220     Document Type: Article

References (55)

1. Einhorn LH, (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99: 4592-4595.
2. Hill JM, Speer RJ, (1982) Organo-platinum complexes as antitumor agents (review). Anticancer Res 2: 173-186.
3. Knight KR, Kraemer DF, Neuwelt EA, (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23: 8588-8596.
4. Knight KR, Kraemer DF, Winter C, Neuwelt EA, (2007) Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25: 1190-1195.
5. Skinner R, Pearson AD, English MW, Price L, Wyllie RA, et al. (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77: 1677-1682.
6. Bess FH, Dodd-Murphy J, Parker RA, (1998) Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 19: 339-354.
7. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J, (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24: 707-713.
8. Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB, (1995) Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 270: 1842-1845.
9. Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ, (1995) Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377: 649-652.
10. Wang D, Lippard SJ, (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320.
11. Kopke RD, Liu W, Gabaizadeh R, Jacono A, Feghali J, et al. (1997) Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 18: 559-571.
12. Baliga R, Ueda N, Walker PD, Shah SV, (1999) Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 31: 971-997.
13. Mukherjea D, Jajoo S, Sheehan K, Kaur T, Sheth S, et al. (2011) NOX3 NADPH oxidase couples transient receptor potential vanilloid 1 to signal transducer and activator of transcription 1-mediated inflammation and hearing loss. Antioxid Redox Signal 14: 999-1010.
14. Ishikawa T, Ali-Osman F, (1993) Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268: 20116-20125.
15. Campbell KC, Rybak LP, Meech RP, Hughes L, (1996) D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res 102: 90-98.
16. Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA, (2005) Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 314: 1052-1058.
17. Ramesh G, Reeves WB, (2005) p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289: F166-174.
18. Thomas JP, Lautermann J, Liedert B, Seiler F, Thomale J, (2006) High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol Pharmacol 70: 23-29.
19. Knox RJ, Friedlos F, Lydall DA, Roberts JJ, (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46: 1972-1979.
20. Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, et al. (2012) Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30: 1034-1041.
21. Chinnaswamy G, Cole M, Boddy AV, Keir M, Price L, et al. (2008) Estimation of renal function and its potential impact on carboplatin dosing in children with cancer. Br J Cancer 99: 894-899.
22. Benoist E, Loussouarn A, Remaud P, Chatal J-F, Gestin J-F, (1998) Convenient and Simplified Approaches to N-Monoprotected Triaminopropane Derivatives: Key Intermediates for Bifunctional Chelating Agent Synthesis. Synthesis 8: 1113-1118.
23. Molenaar C, Teuben JM, Heetebrij RJ, Tanke HJ, Reedijk J, (2000) New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy. J Biol Inorg Chem 5: 655-665.
24. Kalinec GM, Webster P, Lim DJ, Kalinec F, (2003) A cochlear cell line as an in vitro system for drug ototoxicity screening. Audiol Neurootol 8: 177-189.
25. Espreafico EM, Coling DE, Tsakraklides V, Krogh K, Wolenski JS, et al. (1998) Localization of myosin-V in the centrosome. Proc Natl Acad Sci U S A 95: 8636-8641.
26. Karasawa T, Wang Q, David LL, Steyger PS, (2010) CLIMP-63 is a gentamicin-binding protein that is involved in drug-induced cytotoxicity. Cell Death Dis 1: e102.
27. Karasawa T, Wang Q, Fu Y, Cohen DM, Steyger PS, (2008) TRPV4 enhances the cellular uptake of aminoglycoside antibiotics. J Cell Sci 121: 2871-2879.
28. Karasawa T, Wang Q, David LL, Steyger PS, (2011) Calreticulin binds to gentamicin and reduces drug-induced ototoxicity. Toxicol Sci 124: 378-387.
29. Keller A, Nesvizhskii AI, Kolker E, Aebersold R, (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74: 5383-5392.
30. Nesvizhskii AI, Keller A, Kolker E, Aebersold R, (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75: 4646-4658.
31. Wilmarth PA, Riviere MA, David LL, (2009) Techniques for accurate protein identification in shotgun proteomic studies of human, mouse, bovine, and chicken lenses. J Ocul Biol Dis Infor 2: 223-234.
32. Appleton TG, Hall JR, (1970) Complexes with Six-Membered Chelate Rings. I. Preparation of Platinum(II) and Palladium(II) Complexes of Trimethylenediamine and Some Methyl-Substituted Derivatives. Inorg Chem 9: 1800-1806.
33. Chen X, Chen J, Pan Z, Ye Q, Liu W, et al. (2010) Novel Synthesis and Characterization of [Pt(NH3)4](NO3)2. Asian Journal of Chemistry 22: 6493-6496.
34. Priqueler JRL, Butler IS, Rochon FD, (2006) An Overview of 195Pt Nuclear Magnetic Resonance Spectroscopy. Applied Spectroscopy Reviews 41: 185-226.
35. Helliwell JR, Tanley SW, (2013) The crystal structure analysis of the relative binding of cisplatin and carboplatin in a mixture with histidine in a protein studied at 100 and 300 K with repeated X-ray irradiation. Acta Crystallogr D Biol Crystallogr 69: 121-125.
36. Casini A, Mastrobuoni G, Temperini C, Gabbiani C, Francese S, et al. (2007) ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem Commun (Camb): 156-158.
37. Even-Ram S, Doyle AD, Conti MA, Matsumoto K, Adelstein RS, et al. (2007) Myosin IIA regulates cell motility and actomyosin-microtubule crosstalk. Nat Cell Biol 9: 299-309.
38. Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, et al. (2000) Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet 26: 103-105.
39. Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, Castelein CM, et al. (2000) Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am J Hum Genet 67: 1121-1128.
40. Lalwani AK, Atkin G, Li Y, Lee JY, Hillman DE, et al. (2008) Localization in stereocilia, plasma membrane, and mitochondria suggests diverse roles for NMHC-IIa within cochlear hair cells. Brain Res 1197: 13-22.
41. Koch G, Smith M, Macer D, Webster P, Mortara R, (1986) Endoplasmic reticulum contains a common, abundant calcium-binding glycoprotein, endoplasmin. J Cell Sci 86: 217-232.
42. Argon Y, Simen BB, (1999) GRP94, an ER chaperone with protein and peptide binding properties. Semin Cell Dev Biol 10: 495-505.
43. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
44. Ishida R, Takaoka Y, Yamamoto S, Miyazaki T, Otaka M, et al. (2008) Cisplatin differently affects amino terminal and carboxyl terminal domains of HSP90. FEBS Lett 582: 3879-3883.
45. Francis SP, Kramarenko II, Brandon CS, Lee FS, Baker TG, et al. (2011) Celastrol inhibits aminoglycoside-induced ototoxicity via heat shock protein 32. Cell Death Dis 2: e195.
46. Itoh H, Ogura M, Komatsuda A, Wakui H, Miura AB, et al. (1999) A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem J 343 Pt 3: 697-703.
47. Hebert DN, Molinari M, (2007) In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol Rev 87: 1377-1408.
48. Horibe T, Matsui H, Tanaka M, Nagai H, Yamaguchi Y, et al. (2004) Gentamicin binds to the lectin site of calreticulin and inhibits its chaperone activity. Biochem Biophys Res Commun 323: 281-287.
49. Jiang CC, Mao ZG, Avery-Kiejda KA, Wade M, Hersey P, et al. (2009) Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis 30: 197-204.
50. Lin Y, Wang Z, Liu L, Chen L, (2011) Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells. Lung Cancer 71: 291-297.
51. Jentsch S, Rumpf S, (2007) Cdc48 (p97): a "molecular gearbox" in the ubiquitin pathway? Trends Biochem Sci 32: 6-11.
52. Valle CW, Min T, Bodas M, Mazur S, Begum S, et al. (2011) Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLoS One 6: e29073.
53. Liu Y, Hei Y, Shu Q, Dong J, Gao Y, et al. (2012) VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One 7: e35800.
54. Acs K, Luijsterburg MS, Ackermann L, Salomons FA, Hoppe T, et al. (2011) The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks. Nat Struct Mol Biol 18: 1345-1350.
55. Lai MD, Xu J, (2007) Ribosomal proteins and colorectal cancer. Curr Genomics 8: 43-49.